Geneos Wealth Management’s Cellectis CLLS Stock Holding History

Geneos Wealth Management’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$81K	–	2786
2021 Q4	$81K	Buy	+10,000	New	+$98.3K	﹤0.01%	1250
2021 Q3	–	Sell	-7,470	Closed	-$113K	–	2844
2021 Q2	$113K	Sell	7,470 -9,239	-55%	-$155K	﹤0.01%	1118
2021 Q1	$310K	Buy	16,709 +2,675	+19%	+$66.1K	0.01%	783
2020 Q4	$64K	Buy	+14,034	New	+$315K	﹤0.01%	1331
2016 Q3	–	Sell	-247	Closed	-$6K	–	1970
2016 Q2	$6K	Hold	247	–	–	﹤0.01%	1451
2016 Q1	$6K	Buy	+247	New	+$5.95K	﹤0.01%	1433

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geneos Wealth Management's CLLS Position: Q1 2022 in Review

Geneos Wealth Management sold out of Cellectis (CLLS) in Q1 2022, closing a stake of 10,000 shares — an estimated $81K sold.

Geneos Wealth Management first reported a position in CLLS in Q1 2016 and held it in 6 quarters. The position peaked at $310K in Q1 2021. 51 funds tracked by Wall St. Rank hold CLLS as of Q1 2022.

Geneos Wealth Management reported no remaining Cellectis position as of Q1 2022 after selling out during the quarter.
Geneos Wealth Management sold 10,000 Cellectis shares in Q1 2022, an estimated $81K.
Geneos Wealth Management first reported a position in Cellectis in Q1 2016 and held it in 6 quarters.
Geneos Wealth Management's Cellectis position peaked at $310K in Q1 2021.
51 funds tracked by Wall St. Rank held Cellectis as of Q1 2022.

Based on Geneos Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.